Spots Global Cancer Trial Database for aspirin 81 mg
Every month we try and update this database with for aspirin 81 mg cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients | NCT04243122 | Myeloproliferat... Essential Throm... JAK2 Mutation Polycythemia Ve... Primary Myelofi... Venous Thromboe... | Apixaban 2.5 MG... Aspirin 81 mg | 18 Years - | Ottawa Hospital Research Institute | |
Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube | NCT03771651 | Fallopian Tube ... Fallopian Tube ... | Aspirin 81 mg | 18 Years - 99 Years | University of Oklahoma | |
Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma | NCT04066725 | Melanoma (Skin) | Aspirin 81 mg Aspirin 325mg Placebo oral ta... | 18 Years - | University of Utah | |
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients | NCT04243122 | Myeloproliferat... Essential Throm... JAK2 Mutation Polycythemia Ve... Primary Myelofi... Venous Thromboe... | Apixaban 2.5 MG... Aspirin 81 mg | 18 Years - | Ottawa Hospital Research Institute | |
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients | NCT04243122 | Myeloproliferat... Essential Throm... JAK2 Mutation Polycythemia Ve... Primary Myelofi... Venous Thromboe... | Apixaban 2.5 MG... Aspirin 81 mg | 18 Years - | Ottawa Hospital Research Institute |